Current Developments in Pharmacogenomics of Multiple Sclerosis

被引：5
|
作者：
Carlson, Rebecca J. [1 ,2 ]
Doucette, J. Ronald [2 ,3 ,4 ]
Nazarali, Adil J. [1 ,4 ,5 ]
机构：
[1] Univ Saskatchewan, Coll Pharm & Nutr, Mol Cell Biol Lab, Saskatoon, SK S7N 5C9, Canada
[2] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5C9, Canada
[3] Univ Saskatchewan, Dept Anat & Cell Biol, Coll Med, Saskatoon, SK S7N 5C9, Canada
[4] City Hosp, Cameco Multiple Sclerosis Neurosci Res Ctr, Saskatoon, SK, Canada
[5] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5E2, Canada
来源：
CELLULAR AND MOLECULAR NEUROBIOLOGY | 2014年 / 34卷 / 08期
基金：
加拿大健康研究院;
关键词：
Pharmacogenomics; Multiple sclerosis; Interferon-beta; Glatiramer acetate; SNPs; Genome-wide association studies; INTERFERON-BETA THERAPY; GLATIRAMER ACETATE; GENE; SUSCEPTIBILITY; POLYMORPHISMS; MARKERS;
D O I：
10.1007/s10571-014-0095-0
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.
引用
收藏
页码：1081 / 1085
页数：5
相关论文
共 50 条
  • [1] Current Developments in Pharmacogenomics of Multiple Sclerosis
    Rebecca J. Carlson
    J. Ronald Doucette
    Adil J. Nazarali
    Cellular and Molecular Neurobiology, 2014, 34 : 1081 - 1085
  • [2] Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine
    Comabella, Manuel
    Vandenbroeck, Koen
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (05) : 484 - 491
  • [3] IFN-β pharmacogenomics in multiple sclerosis
    Vandenbroeck, Koen
    Urcelay, Elena
    Comabella, Manuel
    PHARMACOGENOMICS, 2010, 11 (08) : 1137 - 1148
  • [4] Pharmacogenomics of Multiple Sclerosis: A Systematic Review
    Hocevar, Keli
    Ristic, Smiljana
    Peterlin, Borut
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [5] Pharmacogenomics of multiple sclerosis: in search for a personalized therapy
    Martinez-Forero, Ivan
    Pelaez, Antonio
    Villoslada, Pablo
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (17) : 3053 - 3067
  • [6] Multiple sclerosis pharmacogenomics Maximizing efficacy of therapy
    Pappas, Derek J.
    Oksenberg, Jorge R.
    NEUROLOGY, 2010, 74 (01) : S62 - S69
  • [7] Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research
    Grossman, Iris
    Knappertz, Volker
    Laifenfeld, Daphna
    Ross, Colin
    Zeskind, Ben
    Kolitz, Sarah
    Ladkani, David
    Hayardeny, Liat
    Loupe, Pippa
    Laufer, Ralph
    Hayden, Michael
    PROGRESS IN NEUROBIOLOGY, 2017, 152 : 114 - 130
  • [8] Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine
    Manuel Comabella
    Koen Vandenbroeck
    Current Neurology and Neuroscience Reports, 2011, 11 : 484 - 491
  • [9] United Europeans for development of pharmacogenomics in multiple sclerosis network
    Vandenbroeck, Koen
    Comabella, Manuel
    Tolosa, Eva
    Goertsches, Robert
    Brassat, David
    Hintzen, Rogier
    Infante-Duarte, Carmen
    Favorov, Alexander
    Escorza, Sergio
    Palacios, Ricardo
    Oksenberg, Jorge R.
    Villoslada, Pablo
    PHARMACOGENOMICS, 2009, 10 (05) : 885 - 894
  • [10] Current treatment of multiple sclerosis
    Gout, O.
    Bensa, C.
    Assouad, R.
    REVUE DE MEDECINE INTERNE, 2010, 31 (08): : 575 - 580
12345